Compare SWBI & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SWBI | PRTA |
|---|---|---|
| Founded | 1852 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Ordnance And Accessories | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 491.2M | 482.3M |
| IPO Year | 2000 | 2013 |
| Metric | SWBI | PRTA |
|---|---|---|
| Price | $14.18 | $9.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 9 |
| Target Price | $14.00 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 499.9K | 392.2K |
| Earning Date | 06-04-2026 | 05-20-2026 |
| Dividend Yield | ★ 3.69% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $474,661,000.00 | $814,000.00 |
| Revenue This Year | $2.62 | $1,111.38 |
| Revenue Next Year | $3.23 | N/A |
| P/E Ratio | $282.30 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.73 | $4.32 |
| 52 Week High | $14.51 | $14.34 |
| Indicator | SWBI | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 79.34 | 56.92 |
| Support Level | $7.91 | $9.54 |
| Resistance Level | N/A | $10.72 |
| Average True Range (ATR) | 0.39 | 0.58 |
| MACD | 0.22 | 0.12 |
| Stochastic Oscillator | 89.34 | 75.99 |
Smith & Wesson Brands Inc is a U.S.-based leader in firearm manufacturing. It operates under one reportable segment: Firearms, which includes firearms distribution and manufacturing services. The company manufactures handguns, long guns, sporting rifles, shooting gear, and suppressor products. The firm's brand portfolio consists of Smith and Wesson, M&P, Thompson/Center Arms, Performance Center, and Gemtech; which are used for defense, law enforcement, hunting, and sporting purposes. The company operates internationally, with the majority of income generated by the U.S. market from its handgun products.
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.